CICC’s initiation is a contrarian bullish signal from a mid-tier firm, but lacks confirmation from EPS revisions or institutional momentum. Monitor for follow-up upgrades or Q1 earnings catalysts before positioning.
PFE drugs
PFE drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 16 $27.20entry
- T+1 · 7mo ago +1.32%α +0.11% · $27.56
- T+5 · 7mo ago −2.03%α −3.01% · $26.65
- T+20 · 6mo ago −4.55%α −10.36% · $25.96
- T+60 · 4mo ago −11.13%α −18.72% · $24.17
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
CICC initiates Pfizer (PFE) at Outperform with a $33 price target, implying 15.6% upside from the current $28.55. The move contrasts with a divided analyst base: 26 analysts show a mean PT of $28.58 and median of $27, with 37% Buy, 31% Hold, and 32% Sell ratings. CICC’s accuracy is 55% (17/31 calls correct), below top-tier firms like Morgan Stanley (71%, 5/7) and Cantor (59%, 10/17). Recent analyst activity includes one upgrade and no downgrades in 30 days. EPS estimates are trending down: -8bps in +1q EPS over 30 days. Institutional flows are mixed, Renaissance Technologies exited while Two Sigma increased position 27x. No insider trades or short interest data available. Earnings date not disclosed.
Impact Score
Recent Analyst Activity
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-04-16 | CICC | initiate | Outperform | $33.00 |
| 2026-04-13 | UBS | maintain | Neutral | $27.00 |
| 2026-04-10 | Morgan Stanley | maintain | Equal-Weight | $28.00 |
| 2026-04-09 | B of A Securities | maintain | Neutral | $26.00 |
| 2026-03-24 | Guggenheim | maintain | Buy | No target |
| 2026-03-17 | HSBC | maintain | Buy | No target |
| 2026-03-02 | Argus Research | upgrade | Buy | No target |
| 2026-02-25 | RBC Capital | initiate | Underperform | $25.00 |
| 2026-02-20 | Barclays | initiate | Underweight | $25.00 |
| 2026-02-09 | Freedom Broker | maintain | Buy | No target |
Over the past 30 days, there has been 1 upgrade (Argus Research) and 0 downgrades. EPS revisions are negative: +1q EPS estimate down 8 cents over 30 days (from $0.7096 to $0.7017), +1y down 8 cents (from $2.831 to $2.823), indicating weakening sentiment despite isolated bullish calls.
Firm Track Record: CICC
CICC accuracy: 55% on 31 calls | avg return: 1.4%
Industry benchmark: mean 51% ± 11%. Top tier: ≥61% (mean + 1σ). Based on 7 firms with ≥5 scored calls.
| Firm | Accuracy | Calls | Avg Return | vs Average |
|---|---|---|---|---|
| Morgan Stanley | 71% | 5/7 | 4.2% | top tier |
| B of A Securities | 67% | 2/3 | -0.1% | top tier |
| Cantor Fitzgerald | 59% | 10/17 | 1.8% | above average |
| Citigroup | 50% | 1/2 | -5% | below average |
| Barclays | 50% | 1/2 | -1.2% | below average |
| Guggenheim | 40% | 2/5 | -1.4% | below average |
| UBS | 40% | 2/5 | -2.7% | below average |
CICC has a 55% accuracy rate (17/31 calls correct), below Morgan Stanley (71%, 5/7) and B of A Securities (67%, 2/3), but above Guggenheim (40%, 2/5) and UBS (40%, 2/5). Its average return of +1.4% ranks in the middle tier. Top-performing firm is Morgan Stanley with +4.2% avg return.
Earnings Estimates
| Period | EPS Est. | EPS Range | Revenue | Revisions (7d) |
|---|---|---|---|---|
| +1q | $0.70 | $0.61 to $0.91 | $14.5B | ↑0 ↓0 |
| +1y | $2.82 | $2.48 to $3.03 | $58.9B | ↑1 ↓0 |
| 0y | $2.96 | $2.80 to $3.17 | $61.2B | ↑1 ↓0 |
| 0q | $0.73 | $0.64 to $0.92 | $13.9B | ↑1 ↓0 |
Cross-Platform Signals
Institutional activity is mixed: Two Sigma increased its stake by 2734.9%, while Renaissance Technologies fully exited a $1.8B position. Norges Bank both entered and later exited, suggesting volatility. No insider trades reported. Congressional buys: Susan Collins (R) bought $15K–$50K on Feb 3; Gilbert Cisneros (D) bought $1K–$15K on Feb 10. Signal divergence: analyst initiation is bullish, but institutional and EPS trends are neutral-to-weak.
Investment Themes
Documents Analyzed
Report based on filing metadata.
Track record
21 reports on PFE
5 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +17.28% at T+60 after the Aug 4, 2026 report. 6 of 8 went positive at some point.
Filters
- Nov 3, 202613d ago 8-K Neutral 2/10 Entry $30.79 Now $28.86 −6.27% settles Feb 2
- Nov 3, 202613d ago 8-K Bullish 6/10 Entry $30.00 Now $28.86 −3.80% settles Feb 1
- Oct 30, 202617d ago Court Ruling Neutral 2/10 Entry $30.67 Now $28.86 −5.90% settles Jan 29
- Oct 23, 202624d ago Institutional Cluster Mixed 3/10 Entry $30.03 Now $28.86 −3.90% settles Jan 21
- Aug 13, 202613w ago Court Ruling Neutral 1/10 Entry $26.79 to $29.23 Now $28.86 +7.73% ▲ +9.11% +12.15% vs SPY
- Aug 12, 202613w ago Insider Buy Bullish 5/10 Entry $26.80 to $29.39 Now $28.86 +7.69% ▲ +9.66% +15.14% vs SPY
- Aug 12, 202613w ago Insider Cluster Bullish 6/10 Entry $26.80 to $29.39 Now $28.86 +7.69% ▲ +9.66% +15.14% vs SPY
- Aug 6, 202614w ago Insider Cluster Bullish 4/10 Entry $26.20 to $30.52 Now $28.86 +10.15% ▲ +16.49% +18.16% vs SPY
- Aug 5, 202614w ago Insider Buy Bullish 5/10 Entry $26.20 to $30.52 Now $28.86 +10.15% ▲ +16.49% +18.16% vs SPY
- Aug 5, 202614w ago Insider Cluster Neutral 3/10 Entry $26.20 to $30.52 Now $28.86 +10.15% ▲ +16.49% +18.16% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers